GlaxoSmithKline plc (LON:GSK) announced a dividend on Wednesday, October 30th, Upcoming.Co.Uk reports. Investors of record on Thursday, November 14th will be given a dividend of GBX 19 ($0.25) per share on Thursday, January 9th. This represents a dividend yield of 1.07%. The ex-dividend date is Thursday, November 14th. The official announcement can be seen at this link.
Shares of GlaxoSmithKline stock traded up GBX 42.20 ($0.55) on Wednesday, hitting GBX 1,782 ($23.28). The company’s stock had a trading volume of 9,020,158 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,770.60 ($23.14). The company has a quick ratio of 0.44, a current ratio of 0.71 and a debt-to-equity ratio of 1,127.74. The firm has a fifty day moving average price of GBX 1,683.65 and a 200-day moving average price of GBX 1,626.04. The company has a market capitalization of $88.90 billion and a P/E ratio of 20.07.
Several equities research analysts recently commented on GSK shares. Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a research report on Friday, August 23rd. Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 15th. Credit Suisse Group started coverage on shares of GlaxoSmithKline in a research report on Tuesday, October 1st. They issued a “neutral” rating and a GBX 1,700 ($22.21) price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,850 ($24.17) price objective on shares of GlaxoSmithKline in a research report on Tuesday, October 15th. Finally, Kepler Capital Markets set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Tuesday, August 27th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of GBX 1,708.93 ($22.33).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: Can systematic risk be avoided?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.